Serum autotaxin levels are associated with Graves' disease

Access this Article

Search this Article

Author(s)

    • Nojiri Takahiro
    • Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan|Department of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan
    • Kihara Shinji
    • Department of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan
    • Murakami Masami
    • Laboratory of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Miyagi, Japan
    • Yatomi Yutaka
    • Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan|Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    • Kurano Makoto
    • Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan|Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    • Araki Osamu
    • Department of Clinical Laboratory Medicine, Gunma University Graduate School of Medicine, Gunma, Japan
    • Nakawatari Kazuki
    • Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan
    • Nishikawa Masako
    • Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    • Kano Kuniyuki
    • Laboratory of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Miyagi, Japan
    • Aoki Junken
    • Laboratory of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Miyagi, Japan

Abstract

<p>Graves' Disease is a representative autoimmune thyroid disease that presents with hyperthyroidism. Emerging evidence has shown the involvement of lysophosphatidic acid (LPA) and its producing enzyme, autotaxin (ATX), in the pathogenesis of various diseases; among them, the involvement of the ATX/LPA axis in some immunological disturbances has been proposed. In this study, we investigated the association between serum ATX levels and Graves' disease. We measured the levels of serum total ATX and ATX isoforms (classical ATX and novel ATX) in patients with untreated Graves' disease, Graves' disease treated with anti-thyroid drugs, patients with subacute thyroiditis, silent thyroiditis, Plummer's disease, or Hashimoto's thyroiditis, and patients who had undergone a total thyroidectomy, as well as normal subjects. The serum total ATX and ATX isoform levels were higher in the patients with Graves' disease, compared with the levels in the healthy subjects and the patients with subacute thyroiditis. Treatment with anti-thyroid drugs significantly decreased the serum ATX levels. The serum ATX levels and the changes in serum ATX levels during treatment were moderately or strongly correlated with the serum concentrations or the changes in thyroid hormones. However, the administration of T3 or T4 did not increase the expression or serum levels of ATX in 3T3L1 adipocytes or wild-type mice. In conclusion, the serum ATX levels were higher in subjects with Graves' disease, possibly because of a mechanism that does not involve hyperthyroidism. These results suggest the possible involvement of the ATX/LPA axis in the pathogenesis of Graves' disease.</p>

Journal

  • Endocrine Journal

    Endocrine Journal 66(5), 409-422, 2019

    The Japan Endocrine Society

Codes

Page Top